Article
T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy
8 Aug 2023
Abstract excerpt
Immune checkpoint blockade is effective for only a subset of cancers. Targeting T-cell priming markers (TPMs) may enhance activity, but proper application of these agents in the clinic is challenging due to immune complexity and heterogeneity. We interrogated transcriptomics of 15 TPMs (CD137, CD27, CD28, CD80, CD86, CD40, CD40LG, GITR, ICOS, ICOSLG, OX40, OX40LG, GZMB, IFNG, and TBX21) in a pan-cancer cohort (N...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
